Canadian Pot Stocks Light Up the TSX: Is MMJ Next?

Aug 30, 2016

While MMJ PhytoTech (ASX:MMJ) has operations all around the globe, for its growing operations it has bunkered down in Canada and already established a solid base there. There are several reasons for this: Canada has a more advanced growing industry than anywhere in the world; its TSX listed medical marijuana stocks are gaining traction on the market and regulations are well and truly opening up.

Read Article

DXB Close to Phase 2 Results: Progresses Promising CKD Product

Aug 16, 2016

Dimerix (ASX:DXB) has just completed its “pre-IND” consultation with US regulatory body the Food and Drug Administration (FDA) with some encouraging outcomes reported. The big news for DXB is that its intended Phase 3 DMX-200 trial will be positioned as an adjunct therapy and not a fixed dose combination therapy.

Read Article

Medical Cannabis Stock MXC Approaching Revenue Uplift?

Jul 22, 2016

Having gained regulatory approval to sell its MGC Derma Anti-Aging line of Cannabidiol-based cosmetic products in the US, MGC Pharmaceuticals (ASX:MXC) recently received its first revenues under its exclusive Californian distribution deal. The first year of the deal is expected to net MXC approximately AU$1.76M – a substantial number for this $51.5M capped company that has only really been on the ASX boards for a short amount of time.

Read Article

US Sales Unlocked for CDY: Pathway to $100M Revenue in Near Term

Jul 20, 2016

After generating strong sales figures across Japan and Australia for its hair loss product evolis®, Cellmid (ASX:CDY) has now taken its first step in cracking the major US market. The global hair loss market is estimated to be around US$7BN annually, with topical treatments accounting for $2.3 billion of that market.

Read Article

New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

Jul 19, 2016

One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.

Read Article

MMJ Now Licensed to Grow Medical Cannabis

Jul 5, 2016

There are just 32 companies in Canada that have a license to grow medical cannabis – and MMJ PhytoTech, Ltd (ASX:MMJ) has just officially joined their ranks – the first ASX listed company to do so. A licence to grow medicinal cannabis is not easy to get your hands on in Canada – over 1200 companies have tried, and over 1000 have failed or given up – indicating the stringent nature of the country’s health regulators.

Read Article
Be alerted as soon as an article is released - Join our mailing list (FREE)
  • close

Are you a sophisticated investor?